» Articles » PMID: 34194673

A Fragment-based Approach to Assess the Ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine Biosynthetic Pathway of

Abstract

The L-arginine biosynthesis pathway consists of eight enzymes that catalyse the conversion of L-glutamate to L-arginine. Arginine auxotrophs (argB/argF deletion mutants) of are rapidly sterilised in mice, while inhibition of ArgJ with Pranlukast was found to clear chronic infection in a mouse model. Enzymes in the arginine biosynthetic pathway have therefore emerged as promising targets for anti-tuberculosis drug discovery. In this work, the ligandability of four enzymes of the pathway ArgB, ArgC, ArgD and ArgF is assessed using a fragment-based approach. We identify several hits against these enzymes validated with biochemical and biophysical assays, as well as X-ray crystallographic data, which in the case of ArgB were further confirmed to have on-target activity against . These results demonstrate the potential for more enzymes in this pathway to be targeted with dedicated drug discovery programmes.

Citing Articles

MnoSR removal in triggers broad transcriptional response to 1,3-propanediol and glucose as sole carbon sources.

Plocinska R, Strus K, Korycka-Machala M, Plocinski P, Kuziola M, Zaczek A Front Cell Infect Microbiol. 2024; 14:1427829.

PMID: 39113823 PMC: 11303327. DOI: 10.3389/fcimb.2024.1427829.


Rv0687 a Putative Short-Chain Dehydrogenase Is Required for In Vitro and In Vivo Survival of .

Bhargavi G, Mallakuntla M, Kale D, Tiwari S Int J Mol Sci. 2024; 25(14).

PMID: 39063103 PMC: 11277061. DOI: 10.3390/ijms25147862.


Amino Acid Biosynthesis Inhibitors in Tuberculosis Drug Discovery.

Guida M, Tammaro C, Quaranta M, Salvucci B, Biava M, Poce G Pharmaceutics. 2024; 16(6).

PMID: 38931847 PMC: 11206623. DOI: 10.3390/pharmaceutics16060725.


New insight into arginine and tryptophan metabolism in macrophage activation during tuberculosis.

Zhang K, Mishra A, Jagannath C Front Immunol. 2024; 15:1363938.

PMID: 38605962 PMC: 11008464. DOI: 10.3389/fimmu.2024.1363938.


Attenuated but immunostimulatory Mycobacterium tuberculosis variant bovis strain Ravenel shows variation in T cell epitopes.

Brenner E, Sreevatsan S Sci Rep. 2023; 13(1):12402.

PMID: 37524777 PMC: 10390569. DOI: 10.1038/s41598-023-39578-5.


References
1.
Mendes V, Blundell T . Targeting tuberculosis using structure-guided fragment-based drug design. Drug Discov Today. 2016; 22(3):546-554. DOI: 10.1016/j.drudis.2016.10.003. View

2.
Prati F, Zuccotto F, Fletcher D, Convery M, Fernandez-Menendez R, Bates R . Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA. ChemMedChem. 2018; 13(7):672-677. PMC: 5915743. DOI: 10.1002/cmdc.201700774. View

3.
Faion L, Djaout K, Frita R, Pintiala C, Cantrelle F, Moune M . Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening. Eur J Med Chem. 2020; 200:112440. DOI: 10.1016/j.ejmech.2020.112440. View

4.
Mendes V, Acebron-Garcia-de-Eulate M, Verma N, Blaszczyk M, Dias M, Blundell T . Mycobacterial OtsA Structures Unveil Substrate Preference Mechanism and Allosteric Regulation by 2-Oxoglutarate and 2-Phosphoglycerate. mBio. 2019; 10(6). PMC: 6879718. DOI: 10.1128/mBio.02272-19. View

5.
Whitehouse A, Thomas S, Brown K, Fanourakis A, Chan D, Libardo M . Development of Inhibitors against tRNA (mG37) Methyltransferase (TrmD) Using Fragment-Based Approaches. J Med Chem. 2019; 62(15):7210-7232. PMC: 6691401. DOI: 10.1021/acs.jmedchem.9b00809. View